Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC)

Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC)

Abstract Introduction Data from two randomized controlled trials (RCTs) showed that injectable cabotegravir (CAB) for pre‐exposure prophylaxis (PrEP) was efficacious in reducing HIV acquisition. The US Food and Drug Administration approved CAB for PrEP in December 2021; Australia in August 2022; Zim...

Full description

Bibliographic Details
Main Authors: Mitchell Warren, Wawira Nyagah, Catherine Verde Hashim, Michelle Rodolph, Robin Schaefer, Heather‐Marie A Schmidt, Rachel Baggaley
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Journal of the International AIDS Society
Subjects:
cabotegravir
HIV
implementation science
PrEP
prevention
product introduction
Online Access:https://doi.org/10.1002/jia2.26094

Internet

https://doi.org/10.1002/jia2.26094

Similar Items